Our company has undergone an on-site inspection for Russian GMP certification.

2017-06-20

Through the official GMP on-site audit by Russia

The Group’s Safety Committee conducted safety training for our company.

2017-06-17

I exercise, I’m happy—Hobby Group Activities

2017-05-10

Gaze at the Lushan Waterfall, and showcase Yino’s charm.

2017-03-27

In the vibrant month of March, with its gentle spring breeze and bright sunshine, now is the perfect time for people to step outside and enjoy the beauty of nature. To breathe in the fresh spring air, savor nature’s soothing embrace, and strengthen the company’s cohesion and unity, Yinruo Rui Company organized two separate outings for all employees on March 23 and March 25—this marked the largest-ever outdoor excursion ever organized by the company. At exactly 8 a.m., as the first rays of morning sunlight greeted us, two tour buses packed with employees departed from the company gate. Along the way, everyone chatted and laughed happily, while the buildings and pastoral landscapes flanking the highway captivated everyone’s attention.

Understand the FDA cGMP 483 Analysis in One Article

2016-11-14

The FDA 483 report, also known as the on-site inspection report, is prepared by U.S. FDA inspectors following current U.S. laws and regulations after conducting an on-site inspection of a company. It summarizes any areas found to be non-compliant with cGMP requirements and is issued to the company. The company must immediately address and rectify all identified non-compliance issues and, within 15 working days of receiving the 483 report, submit a response to the relevant FDA division detailing the corrective actions taken for the non-compliant items. If the FDA determines that the company’s response is appropriate and meets the requirements of applicable laws and regulations, the company will avoid receiving an FDA warning letter. Each fiscal year, the FDA...

The CFDA is stepping up its game—after self-inspections, it will launch rigorous, no-holds-barred spot checks!

2016-11-14

The General Administration Office is publicly soliciting comments on the “Notice on Conducting Verification of Pharmaceutical Manufacturing Processes (Draft for Comments).” To further standardize the management of pharmaceutical manufacturing processes and ensure public drug safety, the State Administration for Market Regulation—Food and Drug Administration has drafted the “Notice on Conducting Verification of Pharmaceutical Manufacturing Processes (Draft for Comments)” and is now openly soliciting public input. Please submit any proposed revisions via email to the Drug and Cosmetic Registration Management Division of the State Administration for Market Regulation—Food and Drug Administration by September 10, 2016. Contact: Xue Yanjiu; Email: yhzcszhc@